Platelet function inhibitors

Citations 1-10 of 10 total displayed.

Most recent content (1 Aug 2009):

Original Articles
Primary Percutaneous Coronary Angioplasty With and Without Eptifibatide in ST-Segment Elevation Myocardial Infarction: A Safety and Efficacy Study of Integrilin-Facilitated Versus Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction (ASSIST)

Michel R. Le May, George A. Wells, Chris A. Glover, Derek Y. So, Michael Froeschl, Jean-François Marquis, Edward R. O'Brien, Michele Turek, Allyson Thomas, Malek Kass, Sachin Jadhav, and Marino Labinaz
Circ Cardiovasc Interv 2009;2:330-338; published online before print as doi:10.1161/CIRCINTERVENTIONS.108.847582.108.847582 [Abstract] [Full text]  

Past content (since Dec 2008):

Original Articles
Primary Percutaneous Coronary Angioplasty With and Without Eptifibatide in ST-Segment Elevation Myocardial Infarction: A Safety and Efficacy Study of Integrilin-Facilitated Versus Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction (ASSIST)

Michel R. Le May, George A. Wells, Chris A. Glover, Derek Y. So, Michael Froeschl, Jean-François Marquis, Edward R. O'Brien, Michele Turek, Allyson Thomas, Malek Kass, Sachin Jadhav, and Marino Labinaz
Circ Cardiovasc Interv published July 22, 2009, doi:10.1161/CIRCINTERVENTIONS.108.847582.108.847582 [Abstract]  

Original Articles
Noncardiac Surgery and Bleeding After Percutaneous Coronary Intervention

Andrew C.Y. To, Guy Armstrong, Irene Zeng, and Mark W.I. Webster
Circ Cardiovasc Interv 2009;2:213-221; published online before print as doi:10.1161/CIRCINTERVENTIONS.108.830158 [Abstract] [Full text]  

Original Articles
A Comparison of Abciximab and Small-Molecule Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Primary Percutaneous Coronary Intervention: A Meta-Analysis of Contemporary Randomized Controlled Trials

Hitinder S. Gurm, Umesh Tamhane, Pascal Meier, P. Michael Grossman, Stanley Chetcuti, and Eric R. Bates
Circ Cardiovasc Interv 2009;2:230-236; published online before print as doi:10.1161/CIRCINTERVENTIONS.108.847996 [Abstract] [Full text]  

Original Article
A comparison of abciximab and small molecule glycoprotein IIb/IIIa inhibitors in patients undergoing primary percutaneous coronary intervention: a meta-analysis of contemporary randomized controlled trials.

Hitinder Gurm, Umesh Tamhane, Pascal Meier, P. Michael Grossman, Stanley J. Chetcuti, and Eric R. Bates
Circ Cardiovasc Interv published April 21, 2009, doi:10.1161/CIRCINTERVENTIONS.108.847996 [Abstract]  

Original Article
Non-Cardiac Surgery and Bleeding after Percutaneous Coronary Intervention

Andrew C. Y. To, Guy Armstrong, Irene Zeng, and Mark W. I. Webster
Circ Cardiovasc Interv published April 21, 2009, doi:10.1161/CIRCINTERVENTIONS.108.830158 [Abstract]  

Original Articles
Stent Parameters Predict Major Adverse Clinical Events and the Response to Platelet Glycoprotein IIb/IIIa Blockade: Findings of the ESPRIT Trial

James E. Tcheng, Ing Haan Lim, Shankar Srinivasan, Joseph Jozic, C. Michael Gibson, J. Conor O'Shea, Joseph A. Puma, and Daniel I. Simon
Circ Cardiovasc Interv 2009;2:43-51; published online before print as doi:10.1161/CIRCINTERVENTIONS.108.809285 [Abstract] [Full text]  

Original Article
Stent Parameters Predict Adverse Clinical Outcomes and Response to Platelet Glycoprotein IIb/IIIa Blockade: Findings of the ESPRIT Trial

James E. Tcheng, Ing Haan Lim, Shankar Srinivasan, Joseph Jozic, C. Michael Gibson, J. Conor O'Shea, Joseph A. Puma, and Daniel I. Simon
Circ Cardiovasc Interv published January 23, 2009, doi:10.1161/CIRCINTERVENTIONS.108.809285 [Abstract]  

Original Article
Stent Parameters Predict Adverse Clinical Outcomes and Response to Platelet Glycoprotein IIb/IIIa Blockade: Findings of the ESPRIT Trial

James E. Tcheng, Ing Haan Lim, Shankar Srinivasan, Joseph Jozic, C. Michael Gibson, J. Conor O'Shea, Joseph A. Puma, and Daniel I. Simon
Circ Cardiovasc Interv published December 3, 2008, doi:10.1161/CIRCINTERVENTIONS.108.809285 [Abstract]  

Controversies in Interventional Cardiology
Should dual antiplatelet therapy after drug-eluting stents be continued for more than 1 year?: Dual Antiplatelet Therapy After Drug-Eluting Stents Should Be Continued for More Than One Year and Preferably Indefinitely

Adnan K. Chhatriwalla and Deepak L. Bhatt
Circ Cardiovasc Interv 2008;1:217-225, doi:10.1161/CIRCINTERVENTIONS.108.811380 [Full text]